By understanding the molecular and cellular mechanisms of VEGF-B action via increased endogenous VEGF-A-VEGFR-2 signaling, VEGF-B could eventually be safely tested as a time- and concentration-controlled therapeutic modality in cardiac ischemia. This evidence concerns the gene KDR and myocardial ischemia.